A multicomponent reaction giving easy and cheap access to a variety of bicyclic 5,5-fused hetero-rings has been developed. Then, an usual rearrangement of imidazo[1,5-]imidazoles or imidazo[1,2-]pyrazoles leading to bi-heterocyclic imidazo- and pyrazolo[1,5-]pyrimidines in the presence of a specific amount of I in THF at room temperature has been achieved. This new method enables the hitherto unreported synthesis of functionalized imidazo- and pyrazolo[1,5-]pyrimidines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071803 | PMC |
| http://dx.doi.org/10.1039/c9ra04609g | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mass Balance of the Indoleamine 2,3-Dioxygenase Inhibitor Navoximod (GDC-0919) in Rats and Dogs: Unexpected Cyanide Release from Imidazo[5,1-]isoindole and Species Differences in Glucuronidation.
Drug Metab Dispos
July 2023
Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (S.W., E.C., J.W., H.L., W.L., S.C.K., L.S.); Pliant Therapeutics, South San Francisco, California (S.M.); and Process Chemistry & Catalysis, F. Hoffmann-La Roche Ltd, Basel, Switzerland (S.P.H., M.B.)
Navoximod (GDC-0919) is a small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) developed to reduce T cell immunosuppression associated with cancer. This study describes the absorption, metabolism, and excretion (AME) of navoximod in rats and dogs after a single oral dose of [C]-navoximod. An unexpected thiocyanate metabolite M1 and a chiral inversion metabolite M51 were captured as the major circulating metabolites in rats, accounting for 30% and 18% of 0-24 hours exposure, respectively.
View Article and Find Full Text PDFImidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.
Eur J Med Chem
April 2021
Department of Experimental Biology, Faculty of Science, Palacký University, Šlechtitelů 27, 78371, Olomouc, Czech Republic. Electronic address:
Pharmacological inhibition of cyclin-dependent kinases has emerged as a possible treatment option for various cancer types. We recently identified substituted imidazo[1,2-c]pyrimidin-5(6H)-ones as inhibitors of cyclin-dependent kinase 2 (CDK2). Here, we report the synthesis of derivatives modified at positions 2, 3, 6 or 8 prepared using Suzuki-Miyaura cross-coupling, halogenation, Dimroth-type rearrangement and alkylation as the main synthetic methods.
View Article and Find Full Text PDFUnusual rearrangement of imidazo[1,5-]imidazoles and imidazo[1,2-]pyrazoles into imidazo[1,5-]pyrimidines and pyrazolo[1,5-]pyrimidines.
RSC Adv
September 2019
Institut de Chimie Organique et Analytique, Université d'Orléans, UMR CNRS 7311 45067 Orléans Cedex 2 BP 6759 France
A multicomponent reaction giving easy and cheap access to a variety of bicyclic 5,5-fused hetero-rings has been developed. Then, an usual rearrangement of imidazo[1,5-]imidazoles or imidazo[1,2-]pyrazoles leading to bi-heterocyclic imidazo- and pyrazolo[1,5-]pyrimidines in the presence of a specific amount of I in THF at room temperature has been achieved. This new method enables the hitherto unreported synthesis of functionalized imidazo- and pyrazolo[1,5-]pyrimidines.
View Article and Find Full Text PDFfusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer.
Proc Natl Acad Sci U S A
February 2017
Department of Pathology and Laboratory Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213;
Thyroid cancer development is driven by known point mutations or gene fusions found in ∼90% of cases, whereas driver mutations in the remaining tumors are unknown. The insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) plays an important role in cancer, yet the mechanisms of its activation in cancer cells remain poorly understood. Using whole-transcriptome and whole-genome analyses, we identified a recurrent fusion between the thyroid adenoma-associated () gene on chromosome 2 and the gene on chromosome 7 located 12 kb upstream of the gene.
View Article and Find Full Text PDFElucidating the Mechanisms of Formation for Two Unusual Cytochrome P450-Mediated Fused Ring Metabolites of GDC-0623, a MAPK/ERK Kinase Inhibitor.
Drug Metab Dispos
December 2015
Departments of Drug Metabolism and Pharmacokinetics (R.H.T., S.M., Q.Y., E.F.C., S.C.K.) and Small Molecule Pharmaceutical Sciences (S.J.R.), Genentech, Inc., South San Francisco, California.
Two isomeric metabolites of GDC-0623 [5-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide], a mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) kinase inhibitor, were identified in radiolabeled mass balance studies in rats and dogs (approximately 5% in excreta) and were also observed in human circulation (nonradiolabeled). Mass spectrometric data indicated that both metabolites had formed a new ring structure fused to the imidazopyridine core. Given their unusual structures, we conducted experiments to elucidate their chemical structures and understand the mechanisms for their formation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!